Advances in Therapy

, Volume 27, Issue 5, pp 285–296 | Cite as

Castration-refractory prostate cancer: New drugs in the pipeline



The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.


castration-refractory prostate cancer docetaxel cabazitaxel abiraterone acetate angiogenesis modulators vaccines 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mathers C, Boschi-Pinto C, Lopez A. Murray C. Cancer incidence, mortality and survival by site for 14 regions of the world. Available at: Accessed May 21, 2010.Google Scholar
  2. 2.
    Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–1490.CrossRefPubMedGoogle Scholar
  3. 3.
    Schrijvers D. Androgen-independent prostate cancer. Recent Results Cancer Res. 2007;175:239–249.CrossRefPubMedGoogle Scholar
  4. 4.
    Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764.PubMedGoogle Scholar
  5. 5.
    Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008;19:1749–1753.CrossRefPubMedGoogle Scholar
  6. 6.
    Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol. 2009;20:703–708.CrossRefPubMedGoogle Scholar
  7. 7.
    Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase iii study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431–5438.CrossRefPubMedGoogle Scholar
  8. 8.
    Eisenhauer EA, Therasse P, Bogaerts PJ, et al. New response evaluation in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.CrossRefPubMedGoogle Scholar
  9. 9.
    Hahn NM, Zon RT, Yu M et al. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009;20:1971–1976.CrossRefPubMedGoogle Scholar
  10. 10.
    Kelly WK. Epothilones in prostate cancer. Urol Oncol. 2010. Nov 12 [Epub ahead of print].Google Scholar
  11. 11.
    Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol. 2009; 20:492–497.CrossRefPubMedGoogle Scholar
  12. 12.
    Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556–563.CrossRefPubMedGoogle Scholar
  13. 13.
    Rosenberg JE, Ryan CJ, Weinberg VK, et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009;27:2772–2778.CrossRefPubMedGoogle Scholar
  14. 14.
    Galmarini CM. Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Investig Drugs. 2009;10:1359–1371.PubMedGoogle Scholar
  15. 15.
    Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs. 2010;21:433–438.CrossRefPubMedGoogle Scholar
  16. 16.
    Drug Discovery & Development Magazine. Phase 3 cabazitaxel trial shows improved survival. Available at: Accessed May 21, 2010.Google Scholar
  17. 17.
    Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol. 2008;8:449–457.CrossRefPubMedGoogle Scholar
  18. 18.
    Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–4571.CrossRefPubMedGoogle Scholar
  19. 19.
    Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel. J Clin Oncol. 2010;28:1496–1501.CrossRefPubMedGoogle Scholar
  20. 20.
    Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489–1495.CrossRefPubMedGoogle Scholar
  21. 21.
    Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–3748.CrossRefPubMedGoogle Scholar
  22. 22.
    Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–1488.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981–991.CrossRefPubMedGoogle Scholar
  24. 24.
    Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790.CrossRefPubMedGoogle Scholar
  25. 25.
    Aragon-Ching JB, Madan RA, Dahut WL. Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol. 2010;Feb 11 [Epub ahead of print].Google Scholar
  26. 26.
    Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol. 2009;2:161–168.CrossRefPubMedGoogle Scholar
  27. 27.
    Ning YM, Gulley JL, Arlen PM, et al. Phase II Trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:2070–2076.CrossRefPubMedGoogle Scholar
  28. 28.
    Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naive castrationresistant prostate cancer. Ann Oncol. 2008;19:746–751.CrossRefPubMedGoogle Scholar
  29. 29.
    Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009;103:1636–1640.CrossRefPubMedGoogle Scholar
  30. 30.
    Safarinejad MR. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study. Urol Oncol. 2010;28:21–27.PubMedGoogle Scholar
  31. 31.
    Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer. 2007;97:1480–1485.CrossRefPubMedGoogle Scholar
  32. 32.
    Mena AC, Pulido EG, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010;21(suppl. 1):S3–S11.CrossRefPubMedGoogle Scholar
  33. 33.
    Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castrationresistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010;21:319–324.CrossRefPubMedGoogle Scholar
  34. 34.
    Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol. 2009;20:913–920.CrossRefGoogle Scholar
  35. 35.
    De Sanctis JB, Mijares M, Suárez A, et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov. 2010;4:144–148.CrossRefPubMedGoogle Scholar
  36. 36.
    Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003;88:822–827.CrossRefPubMedGoogle Scholar
  37. 37.
    Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888–1893.PubMedGoogle Scholar
  38. 38.
    Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532–2539.CrossRefPubMedGoogle Scholar
  39. 39.
    Bagnato A, Spinella F, Rosanò L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol. 2008;86:473–484.CrossRefPubMedGoogle Scholar
  40. 40.
    Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478–2487.CrossRefPubMedGoogle Scholar
  41. 41.
    Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008;14:6270–6276.CrossRefPubMedGoogle Scholar
  42. 42.
    Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 2009;103:434–440.CrossRefPubMedGoogle Scholar
  43. 43.
    Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res. 2009;15:3540–3549.CrossRefPubMedGoogle Scholar
  44. 44.
    Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421–7428.CrossRefPubMedGoogle Scholar
  45. 45.
    Lara PN Jr, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009;20:179–184.CrossRefPubMedGoogle Scholar
  46. 46.
    Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer. 2009;100:1523–1529.CrossRefPubMedGoogle Scholar
  47. 47.
    Rizzi F, Bettuzzi S. Clusterin (CLU) and prostate cancer. Adv Cancer Res. 2009;105:1–19.CrossRefPubMedGoogle Scholar
  48. 48.
    Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs. 2008;17:1955–1962.CrossRefPubMedGoogle Scholar
  49. 49.
    Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102:389–397.CrossRefPubMedGoogle Scholar
  50. 50.
    Chi KN, Hotte SJ, Yu E, et al. Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC). Eur J Cancer. 2009;2(suppl. 7):406.Google Scholar
  51. 51.
    Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics. 2008;3:300–309.CrossRefPubMedGoogle Scholar
  52. 52.
    Molife LR, Attard G, Fong PC, et al. Phase II, twostage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010;21:109–113.CrossRefPubMedGoogle Scholar
  53. 53.
    Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther. 2010;12:77–85.PubMedGoogle Scholar
  54. 54.
    Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001–1011.CrossRefPubMedGoogle Scholar
  55. 55.
    Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099–1105.CrossRefPubMedGoogle Scholar
  56. 56.
    Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–3679.CrossRefPubMedGoogle Scholar
  57. 57.
    Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSFsecreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113:975–984.CrossRefPubMedGoogle Scholar
  58. 58.
    Slovin SF, Kelly WK, Wilton A, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2009;7:E77–E82.CrossRefPubMedGoogle Scholar
  59. 59.
    Ziada A, Barqawi A, Glode LM, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004;60:332–327.CrossRefPubMedGoogle Scholar
  60. 60.
    De Bono JS, Fizazi K, Flechon A, et al. Randomized phase II study of CNTO 328 (C), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone (M) versus M alone in metastatic castration-resistant prostate cancer (CRPC). Presented at: ASCO 2010 Genitourinary Cancers Symposium. Available at: Accessed May 21, 2010.Google Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Dirk Schrijvers
    • 1
  • Peter Van Erps
    • 2
  • Jim Cortvriend
    • 2
  1. 1.Department of Hemato-OncologyZiekenhuisnetwerk Antwerpen-MiddelheimAntwerpBelgium
  2. 2.Department of UrologyZiekenhuisnetwerk Antwerpen-MiddelheimAntwerpBelgium

Personalised recommendations